Morpholines
"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D009025
|
MeSH Number(s) |
D03.383.533.640
|
Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 | 2000 | 0 | 1 | 1 | 2002 | 0 | 2 | 2 | 2004 | 0 | 2 | 2 | 2005 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2008 | 0 | 3 | 3 | 2009 | 2 | 0 | 2 | 2010 | 4 | 1 | 5 | 2011 | 3 | 1 | 4 | 2012 | 3 | 3 | 6 | 2013 | 8 | 4 | 12 | 2014 | 11 | 3 | 14 | 2015 | 0 | 3 | 3 | 2016 | 0 | 2 | 2 | 2017 | 3 | 1 | 4 | 2018 | 2 | 1 | 3 | 2019 | 0 | 1 | 1 | 2020 | 2 | 2 | 4 | 2021 | 0 | 3 | 3 | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
Priestley ES, Banville J, Deon D, Dub? L, Gagnon M, Guy J, Lapointe P, Lavall?e JF, Martel A, Plamondon S, R?millard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. J Med Chem. 2022 07 14; 65(13):8843-8854.
-
Calcaterra SL, Butler M, Olson K, Blum J. The Impact of a PDMP-EHR Data Integration Combined With Clinical Decision Support on Opioid and Benzodiazepine Prescribing Across Clinicians in a Metropolitan Area. J Addict Med. 2022 May-Jun 01; 16(3):324-332.
-
Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022 08; 87(2):373-374.e5.
-
Qi L, Lindsay H, Kogiso M, Du Y, Braun FK, Zhang H, Guo L, Zhao S, Injac SG, Baxter PA, Su JM, Xiao S, Erickson SW, Earley EJ, Teicher B, Smith MA, Li XN. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
-
Carnicelli AP, Hellkamp AS, Mahaffey KW, Singer DE, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Berkowitz SD, Fox KAA, Califf RM, Patel MR. Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. J Am Heart Assoc. 2021 10 05; 10(19):e022485.
-
Raj N, McEachin ZT, Harousseau W, Zhou Y, Zhang F, Merritt-Garza ME, Taliaferro JM, Kalinowska M, Marro SG, Hales CM, Berry-Kravis E, Wolf-Ochoa MW, Martinez-Cerde?o V, Wernig M, Chen L, Klann E, Warren ST, Jin P, Wen Z, Bassell GJ. Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis. Cell Rep. 2021 04 13; 35(2):108991.
-
Gomez DM, Everett TJ, Hamilton LR, Ranganath A, Cheer JF, Oleson EB. Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats. Neuropharmacology. 2021 01; 182:108374.
-
Kurmasheva RT, Erickson SW, Earley E, Smith MA, Houghton PJ. In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer. 2021 02; 68(2):e28772.
-
Everett TJ, Gomez DM, Hamilton LR, Oleson EB. Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance. Prog Neuropsychopharmacol Biol Psychiatry. 2021 01 10; 104:110031.
-
Laird CM, Glode AE, Schwarz K, Lam ET, O'Bryant CL. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. J Oncol Pharm Pract. 2020 Sep; 26(6):1369-1373.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|